Patents by Inventor Kathleen M. Giacomini

Kathleen M. Giacomini has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Platinum anticancer agents
    Patent number: 10392412
    Abstract: Disclosed herein, inter alia, are platinum-based compounds useful for treating cancer.
    Type: Grant
    Filed: November 2, 2016
    Date of Patent: August 27, 2019
    Assignees: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, CORNELL UNIVERSITY
    Inventors: Kathleen M. Giacomini, Swati More, Sook Wah Yee, Ethan Geier, Justin Wilson
  • PCT/US2016/063408
    Publication number: 20180346499
    Abstract: Disclosed herein, inter alia, are platinum-based compounds useful for treating cancer.
    Type: Application
    Filed: November 2, 2016
    Publication date: December 6, 2018
    Inventors: Kathleen M. GIACOMINI, Swati MORE, Sook Wah YEE, Ethan GEIER, Justin WILSON
  • Platinum anticancer agents
    Patent number: 9217007
    Abstract: Described herein are novel platinum-based compounds having the formula: and methods of using platinum-based compounds in the treatment of diseases, such as cancer, that are associated with cells expressing solute transporter proteins.
    Type: Grant
    Filed: February 7, 2014
    Date of Patent: December 22, 2015
    Assignee: The Regents of the University of California
    Inventors: Kathleen M. Giacomini, Swati More
  • PLATINUM ANTICANCER AGENTS
    Publication number: 20140155366
    Abstract: Described herein are novel platinum-based compounds and methods of using platinum-based compounds in the treatment of diseases, such as cancer, that are associated with cells expressing solute transporter proteins.
    Type: Application
    Filed: February 7, 2014
    Publication date: June 5, 2014
    Applicant: The Regents of the University of California
    Inventors: Kathleen M. Giacomini, Swati More
  • USE OF ORGANIC CATION TRANSPORTERS FOR CANCER DIAGNOSIS AND THERAPY
    Publication number: 20100028259
    Abstract: The present invention provides, for the first time, the finding that organic cation transporters (OCTs) are major determinants of the anticancer activity of platinum-based drugs such as oxaliplatin, and therefore have clinical significance for selecting oxaliplatin as the preferred therapy for a cancer that expresses one or more OCTs, such as colorectal cancer or liver cancer. In addition, the OCT genotype can also be used to predict oxaliplatin response or to select therapy. The present invention also provides methods of treating or inhibiting cancers that expresses one or more OCTs by administering a therapeutically effective amount of a platinum-based drug such as an oxaliplatin analog having an organic non-leaving group with an increased size. The present invention further provides methods of sensitizing a therapy resistant cancer to a platinum-based drug such as oxaliplatin by administering a therapeutically effective amount of a nucleic acid encoding an OCT.
    Type: Application
    Filed: April 18, 2007
    Publication date: February 4, 2010
    Applicant: The Regents of the University of California
    Inventors: Kathleen M. Giacomini, Joe W. Gray, Anna Lapuk, Shuzhong Zhang